These are top 10 stocks traded on the Robinhood UK platform in July
On Thursday, TD Cowen’s analyst Charles Rhyee increased the price target for Veeva Systems (NYSE:VEEV) to $261 from $250, while maintaining a Hold rating on the shares. The adjustment comes as Veeva Systems provided a forecast that indicates an uptick in research and development (R&D) growth and a robust adjusted operating income (AOI) margin for fiscal year 2026.
Rhyee noted Veeva’s FY26 guidance suggests revenue in line with consensus estimates and an AOI margin of 42.7%, exceeding the consensus of 40.8%. The raised target reflects the analyst’s observation of improving R&D dynamics within the company. Veeva’s expansion into the top 20 "all in" and the ramping of contracts are expected to drive continued strength in the company’s R&D solutions.
Despite indications of a slowdown in commercial growth, the analyst expects the market’s focus to shift towards Veeva’s robust R&D solutions and the anticipated overall margin improvement for FY26. The new guidance provided by the company is seen as a positive development, likely to influence the stock’s performance.
Veeva Systems specializes in cloud-based software for the global life sciences industry. The company’s services are designed to help organizations manage their R&D, regulatory, quality, and commercial functions effectively. The revised price target reflects confidence in Veeva’s ability to grow its R&D segment and improve profit margins in the coming years.
In other recent news, Veeva Systems reported strong financial results for the fourth quarter of fiscal year 2025, surpassing analysts’ expectations with a revenue of $721 million, a 14% year-over-year increase. The company’s earnings per share (EPS) also exceeded forecasts, coming in at $1.74 compared to the anticipated $1.58. Veeva Systems’ fiscal year 2026 guidance, adjusted for foreign exchange impacts, was ahead of market consensus, further showcasing its robust performance. The company added 20 new customers to its Vault CRM platform, primarily consisting of smaller companies selecting their first CRM system. Analyst firms have responded to these developments, with RBC Capital maintaining an Outperform rating and Raymond (NSE:RYMD) James adjusting their price target to $285 while retaining an Outperform rating. Truist Securities raised its price target for Veeva Systems to $217, maintaining a Hold rating, and Evercore ISI increased their target to $250, acknowledging the company’s strong profitability and market position. Veeva Systems continues to expand its customer base and product offerings, demonstrating confidence in securing top pharmaceutical companies as clients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.